Skip to main content
Year archive

Theranexus — 2022 filings

All 38 regulatory filings released by Theranexus (ALTHX) in 2022, sourced directly from the official regulator.

38 Filings
2022 Period
2022 filings (38)
Filing Released Lang
THERANEXUS PUBLIE SON AGENDA FINANCIER POUR L'EXERCICE 2023
Report Publication Announcement
2022-12-21 French
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2023
Report Publication Announcement
2022-12-21 English
THERANEXUS ANNONCE SA PARTICIPATION A LA ' 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE ', DU 9 AU 12 JANVIER 2023 À SAN FRANCISCO
Regulatory Filings
2022-12-20 French
THERANEXUS ANNOUNCES PARTICIPATION IN THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 9-12, 2023 IN SAN FRANCISCO
Report Publication Announcement
2022-12-20 English
THERANEXUS AND BBDF PRESENT PROGRESS ON THE BATTEN-1 PROGRAM AT THE TRANSLATIONAL RESEARCH CONFERENCE FOR THE MANAGEMENT OF NCLS ON 3 AND 4 NOVEMBER, 2022 IN CHICAGO
Regulatory Filings
2022-11-02 English
THERANEXUS ET LA FONDATION BBDF PRÉSENTENT LES AVANCÉES DU PROGRAMME BATTEN-1 LORS DE LA TRANSLATIONAL RESEARCH CONFERENCE FOR THE MANAGEMENT OF NCLS, LES 3 ET 4 NOVEMBRE 2022 À CHICAGO
Regulatory Filings
2022-11-02 French
THERANEXUS ET INSERM TRANSFERT SIGNENT UNE ALLIANCE STRATÉGIQUE POUR IDENTIFIER DES CANDIDATS MÉDICAMENTS DE THERAPIES INNOVANTES DANS LES MALADIES NEUROLOGIQUES RARES
Regulatory Filings
2022-10-20 French
THERANEXUS AND INSERM TRANSFERT SIGN A STRATEGIC ALLIANCE TO IDENTIFY ADVANCED THERAPY DRUG CANDIDATES FOR RARE NEUROLOGICAL DISEASES
Regulatory Filings
2022-10-20 English
Theranexus publie sa position de trésorerie au 30 septembre 2022
Earnings Release 9M 2022
2022-10-19 French
Theranexus publishes its cash position as of 30 September 2022
Earnings Release 9M 2022
2022-10-19 English
THERANEXUS ANNOUNCES ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2022
Interim / Quarterly Report H1 2022
2022-09-27 English
THERANEXUS ANNONCE SES RÉSULTATS FINANCIERS DU PREMIER SEMESTRE 2022
Interim / Quarterly Report H1 2022
2022-09-27 French
Theranexus et la fondation BBDF finalisent le recrutement de l'étude de phase I/II évaluant Batten-1 dans la maladie de Batten
Regulatory Filings
2022-09-08 French
Theranexus and BBDF finalize recruitment for phase I/II trial to evaluate Batten-1 in Batten disease
Regulatory Filings
2022-09-08 English
BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ DE THERANEXUS CONCLU AVEC LA SOCIÉTÉ PORTZAMPARC
Transaction in Own Shares H1 2022
2022-07-18 French
Theranexus publie sa position de trésorerie au 30 juin 2022
Earnings Release H1 2022
2022-07-12 French
Theranexus publishes its cash position as of 30 june 2022
Capital/Financing Update
2022-07-12 English
THERANEXUS PARTICIPATES IN SEVERAL LEADING SCIENTIFIC CONFERENCES AND BUSINESS CONVENTIONS
Regulatory Filings
2022-06-09 English
THERANEXUS PARTICIPERA À PLUSIEURS CONGRÈS SCIENTIFIQUES ET CONVENTIONS D'AFFAIRES DE RÉFÉRENCE
Regulatory Filings
2022-06-09 French
ASSEMBLÉE GÉNÉRALE DU 22 JUIN 2022 : MISE À DISPOSITION DES DOCUMENTS PRÉPARATOIRES
AGM Information
2022-06-07 French
Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Share Issue/Capital Change
2022-05-25 French
Mise à disposition du document d'enregistrement universel 2021
Report Publication Announcement
2022-04-29 French
URD 2021
Annual Report FY 2020
2022-04-29 French
Theranexus publishes its 2021 full-year results And announces a shift of its strategic focus to rare neurological diseases
Earnings Release FY 2021
2022-04-25 English
Theranexus publie ses résultats annuels 2021 Et annonce son évolution stratégique vers les maladies neurologiques rares
Earnings Release FY 2021
2022-04-25 French
Theranexus publie ses résultats annuels 2021 et annonce son évolution stratégique vers les maladies neurologiques rares
Earnings Release FY 2021
2022-04-25 French
Theranexus publishes its 2021 full-year results And announces a shift of its strategic focus to rare neurological diseases
Earnings Release FY 2021
2022-04-25 English
Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2022-04-06 French
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL
Share Issue/Capital Change
2022-03-23 French
À L'OCCASION DE LA JOURNÉE MONDIALE DES MALADIES RARES 2022, THERANEXUS DÉVOILE SES AVANCÉES SCIENTIFIQUES
Regulatory Filings
2022-02-28 French
THERANEXUS UNVEILS ITS SCIENTIFIC ADVANCES ON THE OCCASION OF WORLD RARE DISEASE DAY 2022
Regulatory Filings
2022-02-28 English
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL
Declaration of Voting Results & Voting Rights Announcements
2022-02-10 French
THERANEXUS ET LA FONDATION BBDF INITIENT LE RECRUTEMENT POUR L'ÉTUDE DE PHASE I/II DANS LA MALADIE DE BATTEN
Regulatory Filings
2022-02-03 French
THERANEXUS AND BBDF START RECRUITMENT FOR PHASE I/II TRIAL IN BATTEN DISEASE PATIENTS
Regulatory Filings
2022-02-03 English
THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 31 DÉCEMBRE 2021 - MISE EN PLACE D'UNE NOUVELLE LIGNE DE FINANCEMENT EN FONDS PROPRE
Capital/Financing Update
2022-01-13 French
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2021 - IMPLEMENTATION OF A NEW EQUITY LINE
Capital/Financing Update
2022-01-13 English
BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE - 2ND SEMESTRE 2021
Capital/Financing Update
2022-01-06 French
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL
Share Issue/Capital Change
2022-01-04 French